Posted by AGORACOM-JC
at 7:42 AM on Friday, November 20th, 2020
Announced that it will work with Shoppers Drug Mart and the event production agency HUMANCONTACT Inc., to deliver an Immersive AR Experience to over 2500 Corporate Staff, Pharmacist-Owners, and Front Store Managers across Canada.
Using the ImagineAR Custom White-label mobile app, Shoppers Drug Mart will integrate dynamic AR into the live streamed virtual event sessions.
“To be selected by Shoppers Drug Mart for their company-wide events validates ImagineAR is the leading AR immersive platform available today,” said Alen Paul Silverrstieen, CEO and President of Imagine AR.
VANCOUVER , BC and ERIE, Pa., Nov. 20, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality Company that enables sports teams, brands and businesses to instantly create their own mobile phone AR campaigns, is pleased to announce that it will work with Shoppers Drug Mart and the event production agency HUMANCONTACT Inc., to deliver an Immersive AR Experience to over 2500 Corporate Staff, Pharmacist-Owners, and Front Store Managers across Canada. Using the ImagineAR Custom White-label mobile app, Shoppers Drug Mart will integrate dynamic AR into the live streamed virtual event sessions.
Karen Bossin , Director, Conferences & Events at Shoppers Drug Mart said; “We are excited to integrate ImagineAR into the launch of our 2021 Virtual Conferences, including on-screen live-streamed AR activations as well as real-time Immersive AR delivered into the homes of our attendees all across Canada . Shoppers Drug Mart is thrilled to be the global pioneer in integrating mobile augmented reality with virtual events.”
Gareth Musico , President of HUMANCONTACT, stated “Our approach to virtual events has been to re-imagine the traditional video call or stream experience and deliver engaging, interactive, and customized content to attendees at home. ImagineAR is an extension of this mission and we’re excited to utilize its capabilities for virtual events and conferences.”
“To be selected by Shoppers Drug Mart for their company-wide events validates ImagineAR is the leading AR immersive platform available today,” said Alen Paul Silverrstieen, CEO and President of Imagine AR. “With the success of this interactive program, we expect to aggressively market our AR Immersive Event Solution to retail companies around the globe.”
This press release is available on the Company’s AGORACOM Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
About HUMANCONTACT Inc.
HUMANCONTACT is the most versatile creative agency of its kind. They are proud to offer clients an unrivaled breadth of capabilities and expertise, always delivered with the personalized service and strategic touch that sets them apart.
Core services include strategy & consultation, event production, design & branding, communications, video production, web development, and more, but there is hardly anything that they can’t do. www.humancontact.com
About ImagineAR
ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.
All trademarks of the property of respective owners.
We encourage you to do your own due diligence and ask your broker if Imagine AR Inc. (cse: IP) is suitable for your particular investment portfolio*.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward- looking information is based on certain key expectations and assumptions made by ImagineAR management. Although Imagine AR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and Imagine AR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Posted by AGORACOM-JC
at 5:16 PM on Thursday, November 19th, 2020
2020 has been a disappointing one for the once euphoric cannabis industry thanks to the fallout of over-hyped and over-financed companies that failed to deliver on a fraction of their promises.
The year 2000 saw the exact same thing happen to “dot-com” companies that failed in even more spectacular fashion. Many investors swore off internet stocks forever.
The smart ones waited to see which companies were real … and the rest was history as we saw the birth and growth of internet companies that delivered real value, products and customers.
The same is about to happen in the Cannabis space. With the market estimated to hit $70 Billion over the next few years, there is very little doubt that winners will be created out of companies delivering real businesses.
Enter Innocan Pharma Corporation (INNO:CSE) (IP4: FSE) and it’s incredible team of accomplished scientists led by CEO Iris Bincovich.
As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products, the latter of which have already announced distribution and manufacturing agreements throughout Europe and the United States.
If you believe in the future of the cannabis and companies delivering real, value-add CBD products, then watch this interview with Innocan CEO, Iris Bincovich.
Posted by AGORACOM-JC
at 10:05 AM on Thursday, November 19th, 2020
Advances Its Silicon Materials for Batteries Development Program
Apollon Solar produces first batch of carbon coated nano silicon powders.
HPQ Silicon is developing a portfolio of silicon–based products using proprietary innovative low cost and scalable processes. The target objective is to produce high value speciality Silicon products needed by batteries and electric vehicle manufactures.
MONTREAL, Nov. 19, 2020 – Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or “the Company”) ( TSX-V: HPQ ; FWB: UGE ; Other OTC : URAGF ), is pleased to announce that, in addition to manufacturing samples of porous Silicon nanopowders of different sizes (2 nm to 1 µm) and pore structures (Microporous (<5nm), Mesoporous (5nm – 50nm) or Macroporous (>50nm)), HPQ Silicon R&D consortium member Apollon Solar of France has also commenced evaluation of different carbon encapsulating processes for Silicon nanopowders. As part of this HPQ – led effort, Apollon has delivered a first batch of carbon coated nano silicon powders to Professor Lionel Roué team at the Institut National de la Recherche Scientifique (INRS) for evaluation. Other batches of silicon materials (coated and non-coated) are being prepared and will be sent the INRS for evaluations over the coming weeks.
ACCELERATINGR&D ON NANO SILICON POWDERS CARBON COATING
Apollon proposed that in addition to carbon coating their porous Silicon nanopowders they could use commercially available but expensive (US$ 22,500 per Kg) 1 nano silicon powders to evaluate the efficiency of different carbon coating processes. Using powders with the same characteristic as the powders to be produced by HPQ NANO PUREVAP™NANOSILICONREACTOR should reduce our R&D timeline and give us valuable insight moving forward.
“Producing carbon coated nano silicon powders for testing this early in the process is another demonstration of the depth and flexibility of HPQ’s R&D consortium. HPQ iscommittedtostaying at the forefront of Silicon for batteries R&D.This latest effort is part of our plan to produce productsfor renewable energy storage participantsand electric vehicle manufacturers who continue to search for cost effective ways of increasing the Silicon contained in their batteries.,” said Bernard Tourillon, President and CEO HPQ Silicon. “Silicon’spotential to meet energy storagedemand is undeniable,generatingmassive investments,andserious industry interest.We are very confidentthat demand for the Silicon materials wewillproduce,with ourlow-cost scalable processes,will be high demand bybatteries and EV manufacturersin this renewable energy revolution.”
Tesla’s latest battery day presentation confirmed that the future of battery anodes will include Silicon. Tesla’s “… plans on removing graphite from the anode…”2, points to the need for innovative silicon solutions which HPQ is focused on, to make Silicon – based anodes technically and economically feasible for the production of more efficient rechargeable Li-batteries.
Presently, Silicon is used in a blended form with graphite and typically only represents around 5% by wt , which explains the limited performance improvements achieved to date. The primary hurdle to increasing Silicon anode content in Li-ion batteries is the mitigation of Silicon swelling and cracking during the lithiation phase 3 in order to achieve a cycling stability comparable to graphite.
Ongoing R&D indicates that the two most promising avenues for resolving these issues are:
Nanosizing Silicon powders to eliminate cracking during the lithiation phase.
Encapsulating the Silicon in order to improve its swelling and cracking characteristics.
HPQ is in the forefront of addressing these issues with the PUREVAP™NSiR process and our ongoing work on porous silicon nanopowders and carbon coating nano silicon.
Silicon (Si), also known as silicon metal, is one of today’s key strategic materials needed for the decarbonization of the economy and the Renewable Energy Revolution (“RER”).
Silicon is the most abundant element in earth’s crust but does not exist in its pure state and must be extracted from quartz (SiO 2 ) in what has historically been a capital and energy intensive process. HPQ is building a portfolio of silicon–based products using innovative scalable processes. The target objective is to produce high value speciality Silicon products using technologies that will reduce energy consumption, GHG’s, and carbon footprint.
Working with PyroGenesis Canada Inc.(TSX-V: PYR) , a high-tech company that designs, develops, manufactures and commercializes plasma – based processes, HPQ is developing:
The PUREVAP™“Quartz Reduction Reactors” (QRR) , an innovative process (patent pending), which will permit the one step transformation of quartz (SiO 2 ) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential ;
• HPQ believes it will become the lowest cost (Capex and Opex) producer of silicon (Si) and high purity silicon metal (3N – 4N Si);
Through its 100% owned subsidiary HPQ NANO Silicon Powders Inc, the PUREVAP™Nano Silicon Reactor(NSiR) , a new proprietary process that can use different purities of silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires.
• HPQ believes it can also become the lowest cost manufacturer of spherical Si nanopowders and silicon-based composites needed by manufacturers of next-generation lithium-ion batteries .
• During the coming months, spherical Si nanopowders and nanowires silicon-based composite samples requested by industry participants and research institutions’ will be produced using PUREVAP™SiNR .
HPQ is also working with industry leader Apollon Solar of France to:
Use their patented process and develop a capability to produce commercially porous silicon (Si) wafers and porous silicon (Si) powders.
• The collaboration will allow HPQ to become the lowest cost producer of porous silicon wafers for all-solid -state batteries and porous silicon powders for Li-ion batteries.
• Develop the hydrogen generation potential of Silicon nanopowders for use with the Gennao™ system.
• Commercialize, exclusively in Canada, and non-exclusive in the U.S.A., the Gennao™ H 2 system and the chemical powders required for the hydrolysis production of Hydrogen (“H2”).
This News Release is available on the company’s CEO Verified Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
Disclaimers:
The Corporation’s interest in developing the PUREVAP™ QRR and any projected capital or operating cost savings associated with its development should not be construed as being related to the establishing the economic viability or technical feasibility of any of the Company’s Quartz Projects.
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-lookingstatements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the security’s regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information contact
Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011 Patrick Levasseur, Vice-President and COO Tel: (514) 262-9239 http://www.hpqsilicon.com Email: [email protected]
Posted by AGORACOM-JC
at 7:43 AM on Thursday, November 19th, 2020
Announced that it has signed an agreement with packaged foods wholesale distributor Beijing Jingying Corporate Management Ltd. to bring Peak’s Cubeler Lending Hub financing solution to BJM and its more than 250,000 retail clients
Peak launched a financing program powered by Lending Hub in October specifically designed to provide better cash flow flexibility to large wholesale distributors and their retail clients
The program, which recorded its first transactions a week ago, allows for retailers to have up to 90% of the price of the products they purchase from participating distributors financed by the Lending Hub’s banks and lending institution
Montreal, Quebec–(November 19, 2020) – Peak Positioning Technologies Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that it has signed an agreement with packaged foods wholesale distributor Beijing Jingying Corporate Management Ltd. (“BJM”) to bring Peak’s Cubeler Lending Hub financing solution to BJM and its more than 250,000 retail clients.
Peak launched a financing program powered by Lending Hub in October specifically designed to provide better cash flow flexibility to large wholesale distributors and their retail clients. The program, which recorded its first transactions a week ago, allows for retailers to have up to 90% of the price of the products they purchase from participating distributors financed by the Lending Hub’s banks and lending institutions.
BJM is the second wholesale distributor to subscribe to the program joining consumer electronics product distributor Beijing Dianjing Company Ltd., which helped launch the program with its 60,000 plus online retail clients. BJM is a major distributor of a variety of popular products from China Oil and Foodstuffs Corporation (COFCO), for which it has exclusive distribution rights to approximately 200,000 Petro-China convenience stores and on online retail giant JD.com. COFCO is a state-owner food processing company. It’s China’s largest food processor, manufacturer and commodities trader. With operations in Japan, the US, the UK, Australia and Canada, it’s one of the largest agribusiness groups in all of Asia.
Most recently BJM became an authorized distributor of RELX brand e-cigarettes, one of China’s most popular and fastest growing brands of e-cigarettes, sold at over 3,000 retail outlets throughout the country.
“We are very pleased to be joining this wonderful financing program created by Peak,” commented Mr. Yang Zhang, CEO of BJM. “We have no doubt that this will be extremely beneficial to most of our clients and we very much look forward to getting them signed up as quickly as possible,” he went on to say.
“I would like to take this opportunity to welcome Mr. Zhang and BJM to our new Lending Hub financing program and look forward to working with him and his team,” said Peak Group China CEO, Mr. Liang Qiu. “BJM’s arrival to the program brings us a great mixture of online and offline stores and allows us to further showcase Lending Hub’s versatility when it comes to its ability to help businesses up and down the supply chain whether they operate predominantly online or offline. We’ve noticed somewhat of a blurring of the online and offline retail space lately including JD.com announcing plans for a network of 5 million brick-and-mortar stores in the next 3 years. I think with Lending Hub’s ability to process and analyze data coming from its member businesses both online and offline, Peak is ideally positioned to play an increasingly important role in this blurring or evolution of the retail space,” concluded Mr. Qiu.
Wall Street Reporter’s NEXT SUPER STOCK Livestream – November 19, 2020
Peak will be a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK livestream conference on Thursday November 19, 2020 at 12:30pm EST. CEO Johnson Joseph will discuss the addition of BJM to Peak’s new financing program, the potential annual revenue it could bring and answer investor audience questions. Those interested can click the following link to register and join the livestream: Next Super Stock Livestream Registration
About Peak Positioning Technologies Inc.:
Peak Positioning Technologies Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://www.peakpositioning.com.
For more information, please contact:
CHF Capital Markets Cathy Hume, CEO 416-868-1079 ext.: 251 [email protected]
Peak Positioning Technologies Inc. Johnson Joseph, President and CEO 514-340-7775 ext.: 501 [email protected]
This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.
Posted by AGORACOM-JC
at 7:15 AM on Thursday, November 19th, 2020
Announced the signing of a referral and partnership agreement with iSTOC Ltd. of Finland to provide a complete end-to-end integrated COVID-19 management platform consisting of rapid mobile testing, integrated lab results, and venue tracing with real-time, automated exposure alert notification capabilities.
The combined solution arising from this partnership will create a Covid-19 tracing and testing solution that is FDA and HIPPAA compliant and can be deployed by any government, NGO, healthcare organization or enterprise-level organization worldwide.
VANCOUVER, British Columbia, Nov. 19, 2020 — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick and mortar space, is pleased to announce the signing of a referral and partnership agreement with iSTOC Ltd. of Finland to provide a complete end-to-end integrated COVID-19 management platform consisting of rapid mobile testing, integrated lab results, and venue tracing with real-time, automated exposure alert notification capabilities.
The combined solution arising from this partnership will create a Covid-19 tracing and testing solution that is FDA and HIPPAA compliant and can be deployed by any government, NGO, healthcare organization or enterprise-level organization worldwide.
Loop Insights CEO Rob Anson stated : “I am very honoured for the opportunity to partner with Jarmo and his world-class team at iSTOC. These have been very trying times, and as we head into the fall-winter months, every country is in desperate need of a complete transformative solution that enables the resumption of in-person schooling, travel, commerce, and a return of spectators to live events. This is a very big day for the Company as our partnership with iSTOC positions us as a true global leader regarding complete Covid-19 management solutions.”
iSTOC WILL HAVE FACILITATED MILLIONS OF TESTS IN AT LEAST 50 COUNTRIES BY 2020 END iSTOC has developed a disruptive mobile solution called IDA (immediate diagnostics and analytics) and has launched rapid tests that can detect antibodies for different infectious diseases from a small drop of blood, plus a mobile diagnostics solution for analyzing the test results, as well as, geographical mapping capabilities for the spread of infectious diseases such as Covid-19. The globally scalable end-to-end solution has proven to be a powerful product and service, offering significant and innovative new business opportunities for iSTOC business partners and customers.
The IDA Platform digitalizes and analyses lateral flow tests (LFTs), including all major infectious diseases. Unlike PCR tests, LFTs detect the antibodies for diseases like Covid-19, which means that LFTs do not show early acute infections but can detect infections beyond the first 14 days of the infection, after which PCR is ineffective.
All diagnostics are performed using smartphone cameras, making it possible to deliver on three important diagnostic criteria: high quality, accessibility even in the most remote locations, and affordability in countries with lower income and high out of pocket costs.
iSTOC has facilitated millions of tests in over 25 countries and expects to be present in at least twice as many countries by the end of 2020.
LOOP AND iSTOC DELIVER FDA AND HIPPAA COMPLIANT INTEGRATED COVID-19 MANAGEMENT SOLUTION
The companies have partnered to deliver a fully compliant solution with both FDA and European regulations and is also HIPAA compliant. Loop’s AI-powered data platform and iSTOC’s front end testing application will integrate to deliver a turn-key end-to-end Covid-19 management solution.
Leveraging Loop’s Anonymized Digital ID and Digital Wallet Application and iSTOC’s leading testing and mobile telemedicine application, the combined solution will provide a complete product offering with safety and data security protecting all personally identifiable information. iSTOC’s real-time dashboard decisioning leverages “big data” to enable comprehensive review and ensure safer environments such as venues and workplaces.
PARTNERSHIP PROVIDES LOOP THE ABILITY TO ADDRESS GLOBAL OPPORTUNITIES On October 29th, Loop Insights and Amazon Web Services (AWS) hosted a webinar to showcase the Company’s Venue Tracing Solution to a global audience of hospitality businesses that resulted in 1,000 attendees from industries including but not limited to:
Hotels
Airlines
Venue Owners
Sports & Entertainment Organizations
The Company has been engaged in several discussions with global hospitality companies in search of a solution to enable the safe resumption of their operations and ensure their long-term viability and sustainability.
As a result of the partnership with iSTOC, Loop Insights now can offer rapid test and lab results to any organization searching for a complete end-to-end Covid-19 solution across Europe and dozens of other countries where iSTOC has existing adoption and service contracts. The combined product offering featuring Loop’s end-to-end solution will focus on large scale government opportunities, hospitals, stadiums, long-term care facilities, construction sites, HR administration, campuses, airlines, cruise ships, resorts, and government and corporate buildings that need to safely reopen and resume operations.
iSTOC’s CEO, Jarmo Järvenpää stated, “Loop Insights’ venue tracing platform is the perfect complement to our best-in-class immediate diagnostics and analytics of infectious disease application. For the first time, a combined product and service offering will enable a complete end to end management solution.”
LOOP IN DISCUSSIONS WITH CRUISE INDUSTRY AS CARNIVAL POSTS $3 BILLION QUARTERLY LOSS DUE TO COVID-19
According to Guardian.com, Carnival reported a $3B quarterly loss due to the Covid-19 pandemic. With airlines as the first industry adopting rapid testing to reduce or eliminate the need for 14-day quarantine periods, the cruise industry is looking to embrace and adopt technologies that can allow them to safely reopen with contact tracing and best of breed protocols and processes for contactless solutions in order for their economic recovery to begin. To date, Loop has been actively involved in many conversations with not only airports and airlines but the cruise industry as well. The Company believes as a result of the partnership with iSTOC, the Company is well-positioned to deliver the complete end to end solution to enable the cruise industry to reopen its operations and instill confidence in travellers safely.
This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/LoopInsights
About iSTOC: iSTOC is a Finland-based health-tech company that operates globally and is a preferred vendor for several health organizations. iSTOC integrates Point of Care diagnostics, machine vision, mobile technology and cloud computing into one reliable platform. iSTOC has developed a disruptive mobile solution IDA (immediate diagnostics and analytics). The end-to end solution has proven to be a powerful product and service, offering significant and innovative new business opportunities for iSTOC partners and customers around the world. iSTOC IDA Platform digitalizes and analyses lateral flow tests (LFT), including all major infectious diseases as well as blood typing, female and reproductive health and drugs of abuse. More information about iSTOC in the company webpage https://istoc.io /
About Loop Insights : Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.
This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:07 AM on Thursday, November 19th, 2020
Announced that Kai Medical Laboratory (“KAI”) will be introducing its new KAI ABC RT-PCR test protocol to differentiate between Influenza A/B and COVID-19 (“ABC”), which will be vital in the diagnosis and treatment of respiratory pathogens
The new KAI ABC RT-PCR test protocol is expected to be ready for the market in the first week of December, in time for the most recent 9,000 unit, $1,000,000 order for a film & television production
VANCOUVER BC / November 19, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) will be introducing its new KAI ABC RT-PCR test protocol to differentiate between Influenza A/B and COVID-19 (“ABC”), which will be vital in the diagnosis and treatment of respiratory pathogens.
The new KAI ABC RT-PCR test protocol is expected to be ready for the market in the first week of December, in time for the most recent 9,000 unit, $1,000,000 order for a film & television production.
Empower Clinics Chairman and CEO, Steven McAuley, stated “Kai Medical Laboratory with its team of scientists and lab experts are opening new channels of expansion for Empower in research and diagnostics, enabling the company to access dramatically larger national and international markets for healthcare products. We have a number of exciting developments coming that expand and diversify our reach both through the lab and within our clinic layer that have direct access to patients”
MULTIPLE BENEFITS OF KAI ABC RT-PCR RANGE FROM EARLY AND CORRECT DIAGNOISIS TO PACKAGED COST SAVINGS
COVID-19 and influenza viruses have a similar disease presentation. They both cause respiratory disease, which presents as a wide range of illness from asymptomatic or mild through to severe disease and death. As such, the benefits of this KAI ABC RT-PCR test protocol being able to differentiate between the Flu and COVID-19 are invaluable as follows:
First, it is vital in the diagnosis and treatment of respiratory pathogens. As most COVID-19 testing now primarily focuses on COVID-19 only, diagnosing the difference between the two will be crucial to treatment, health outcomes, and overall health of the population. Specifically, differentiating the pathogens will help medical professionals quickly diagnose and treat more efficiently & efficaciously.
Second, it is a vital tool in helping slow down the spread of COVID-19. Specifically, the speed of transmission is an important point of difference between the two viruses. Influenza has a shorter median incubation period (the time from infection to appearance of symptoms) than COVID-19. Transmission in the first 3-5 days of illness is a major driver for the spread of viral infections. This makes COVID-19 extremely difficult to contain. This is why testing to differentiate the viral infections becomes critical to “slowing the spread.”
Finally, affordability and efficiency. Though the overall cost of an ABC RT-PCR test is approximately 15% to 25% more expensive than an RT-PCR test, providing analysis on all three viruses is significantly cheaper and more affordable than testing for them separately. Moreover, from an efficiency point of view, simultaneously confirming a patient has the flu and does not have COVID-19 from the same collected specimen, allows them, their families and work colleagues to return to a normal life much faster.
BENEFITS TO EMPOWER CLINICS
From a business development point of view, Empower has a high degree of confidence the multiple benefits listed above will translate into significant new business, as evidenced already by the transition of the Company’s recent $1,000,000 test order by a film & tv production from RT-PCR to the new KAI ABC RT-PCR protocol.
“From an R&D perspective, Kai Medical Laboratory is focused on the future and new innovative quality testing to better understand the epidemiology and contagion containment that we have all experienced during this pandemic.” said Yoshi Tyler, President Kai Medical Laboratory. She further states “Kai Medical will continue to be at the forefront of science and innovative quality care by providing value added services, accuracy, and consistency. As such, we believe this will be the first of many successful R&D product announcements in the near future.”
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER
Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the fact that Kai Medical Laboratory will complete the development of ABC RT-PCR test; the development of new accounts using the new test; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 7:30 PM on Wednesday, November 18th, 2020
Announced that it has closed the 1st tranche of a Unit financing. In connection with the closing, the Company issued 1,838,000 Units at a price of $0.55 per Unit, for gross proceeds of $1,010,900.
Each Unit consists of one (1) common share and one (1) warrant. Each warrant entitles the holder to purchase one common share of the Company, at an exercise price of $0.75 per share, for a period of two years from the date of issuance.
Vancouver, British Columbia–(November 18, 2020) – TransCanna Holdings Inc.(CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company“) is pleased to announce that it has closed the 1st tranche of a Unit financing. In connection with the closing, the Company issued 1,838,000 Units at a price of $0.55 per Unit, for gross proceeds of $1,010,900. Each Unit consists of one (1) common share and one (1) warrant. Each warrant entitles the holder to purchase one common share of the Company, at an exercise price of $0.75 per share, for a period of two years from the date of issuance. The warrants are subject to an acceleration right that allows the Company to give notice of an earlier expiry date if the Company’s share price on the CSE or such other stock exchange the Company’s shares may be trading on is equal to or greater than $1.25 for a period of 20 consecutive trading days. 63,040 Broker’s warrants were issued in connection with finder’s fees payable and in lieu of 8% cash finder’s fees, 63,040 Broker’s Units were issued.
The private placement is subject to the approval of the Canadian Securities Exchange (“CSE”) and the securities will be subject to a four-month hold period under securities laws. The Company intends to use the net proceeds from the private placement for working capital purposes.
The Company did not file a material change report more than 21 days before the expected closing of the private placement as the details of the private placement and the participation therein by related parties of the company were not settled until shortly prior to closing and the company wished to close on an expedited basis for sound business reasons and in a time frame consistent with usual market practices for transactions of this nature.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.
On behalf of the Board of Directors Bob Blink, CEO 604-349-3011
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 5:04 PM on Wednesday, November 18th, 2020
ThreeD Capital (IDK:CSE / IDKFF:OTCQB) prides itself on discovering great companies before everyone else … and it casts a wide net to find the best of the best ranging from precious metals companies to completely disruptive companies. Moreover, IDK isn’t afraid to invest and be patient in both public and private companies.
As such, it’s like and ETF for ground floor investments that small cap investors would either be unable to find (private) or unable to participate in (early round accredited investors)
It is able to do all this and do it well under the leadership of one of the greatest investors in Canadian history – Sheldon Inwentash, the Founder, Chairman and CEO of IDK. Inwentash’s track record of success speaks for itself, including successful exits in the hundreds of millions and even billions in previous years. His last company commanded a market cap north of $1 Billion and now he’s looking to create another success out of IDK.
Will he do it? He’s off to a good start so far by quietly making investments over the past couple of years that are now starting to pay off. In this interview Inwentash discusses:
His investment philosophy
A couple of his recent investments in Peak Fintech (PKK:CSE) and Loop Insights (MTRX:TSXV)
Why he’s investing heavily in gold juniors
Why he’s investing heavily in blockchain companies + their tokens
Best of all, after one hell of a ride for the financial markets in 2020, Inwentash talks about why 2021 “is the year to be all in”
Watch this great interview … because when a legendary financier speaks, every small cap investor should be listening.
Posted by AGORACOM-JC
at 12:39 PM on Wednesday, November 18th, 2020
Avicanna (AVCN: TSX) (AVCN: OTCQX) (0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.
Third Quarter Highlights
$882K in revenue, an increase of 24% from Q2-2020,
Double-digit growth quarter over quarter from Q4-2019
Reached a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams.
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:
1. The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year.
2. Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.
3. Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.
Posted by AGORACOM
at 8:18 AM on Wednesday, November 18th, 2020
Generates 21.2% Sequential Revenue Growth, with Record Gross Revenues of $19.6 Million and Continued Positive Adjusted EBITDA (1) of $4.5 million
Reports Strong Combined Gross Margin of 54.7% (1) Driven by Improved Harvest Yields and Higher Wholesale Volumes
Expects Full Year Gross Revenues of Approximately $61 Million – $63 Million with Adjusted EBITDA of 8-10% (1)(2)
OAKLAND, CA and TORONTO, Nov. 18, 2020 /CNW/ – Harborside Inc. (“Harborside” or the “Company”) (CSE: HBOR) (OCTQX: HBORF), a California-focused, vertically integrated cannabis enterprise, today reported its financial results for the period ending September 30, 2020 (“Q3 2020”). The Q3 2020 financial report and corresponding management’s discussion and analysis (collectively the “Q3 Filings”) are available for download from the Company’s investor website,investharborside.com, and on the Company’sSEDAR profile. Unless otherwise indicated, all dollar amounts in this press release are in U.S. dollars.
Management Commentary
“We’ve implemented strong operational improvements that have continued our progress towards long term profitability and sustained growth. Harborside continues to be one of the leaders in the Northern California market,” said Peter Bilodeau, Chairman, and interim Chief Executive Officer. “As our production capacity is expected to ramp up in early 2021, following the completion of the planned upgrades at our Salinas greenhouse facility, we expect to be well-positioned to accelerate our growth and continue to gain wholesale market share. I’m thrilled with how far Harborside has come this year and look forward to further growth in 2021.”(2)
Q3 2020 Financial Results and Highlights (2)(3)
Q3 2020
Q2 2020
Q1 2020
Q4 2019
Retail Revenues
$10,681,897
$10,940,143
$10,181,471
$9,511,221
Wholesale Revenues(a)
$8,890,723
$5,208,439
$4,456,775
$2,185,701
Total Gross Revenues(a)
$19,572,620
$16,148,582
$14,638,246
$11,696,922
Retail Gross Profit(e)
$5,353,429
$5,601,565
$5,219,890
$4,903,947
Wholesale Gross Profit(a)(e)
$5,360,764
$2,435,952
$787,964
-$1,373,186
Total Gross Profit(a)(e)
$10,714,193
$8,037,517
$6,007,854
$3,530,761
Retail Gross Margin(b)(e)
50.10%
51.20%
51.30%
51.60%
Wholesale Gross Margin(a)(e)
60.30%
46.80%
17.70%
-62.80%
Total Gross Margin(e)
54.70%
49.80%
41.00%
30.20%
G&A/Professional Fees(c)(d)
$6,783,987
$6,764,781
$5,786,573
$7,621,971
Adjusted EBITDA(e)
$4,473,046
$642,025
$431,562
-$2,796,178
NOTES:
a. Not including excise taxes or biological asset adjustments.
b. Retail gross margin in Q1 2020 and Q2 2020 are slightly affected by additional expenditures on personal protective equipment and other safety measures due to the COVID-19 pandemic. Retail gross margin in Q2 2020 and Q3 2020 include additional pay for the Company’s front line workers and expenses relating to the impacts of the civil unrest in the Bay Area to certain of the Company’s retail stores.
c. Professional Fees for the fourth quarter of 2019 include approximately $953,000 in one-time fees and accruals for legal matters
d. Professional Fees for Q2 2020 and Q3 2020 include approximately $977,000 and $1,115,000, respectively, in one-time costs relating to the audits and restatements of certain of the Company’s previous financial statements.
e. This is a non-IFRS reporting measure. For a reconciliation of this to the nearest IFRS measure, see “Use of Non-IFRS Measures” and “Non-IFRS Measures” in the Company’s management discussion and analysis for September 30, 2020.
Q3 2020 Financial Summary
During Q3 2020, Harborside generated total gross revenues of approximately $19.6 million. This represented 21.2% sequential growth over the second quarter of 2020 (“Q2 2020”) and a 42.9% year-over-year increase when compared to the approximately $13.7 million of gross revenues reported in the period ending September 30, 2019 (“Q3 2019”). Combined gross profit before excise taxes and adjustments for biological assets was approximately $10.7 million, an 85.8% year-over-year increase as compared to the $5.8 million reported in Q3 2019. On a year over year basis, combined gross margins increased from 42.1% in Q3 2019 to 54.7% in Q3 2020(1).
Harborside’s wholesale operations reported gross wholesale revenues of approximately $8.9 million, representing 70.7% sequential growth compared to Q2 2020 and a year-over-year increase of 169.4% as compared to the approximately $3.3 million in gross revenues reported for Q3 2019. The year-over-year increase in gross wholesale revenues was primarily due to improved harvest yields and production of premium flower, higher sales volumes, and higher average prices per pound at the Company’s 47-acre integrated production campus in Salinas, California (the “Salinas Facility”). As compared to gross wholesale revenues, wholesale gross margins increased from -22.1% in Q3 2019 to 60.3% in Q3 2020(1).
The Company’s retail operations generated revenues of approximately $10.7 million, a 2.8% increase as compared to the approximately $10.4 million realized in Q3 2019, with gross margins improving from 48.5% to 50.1% on a year-over-year basis, despite increased costs for safety and staffing related to COVID-19 and inventory losses experienced during the civil unrest that occurred in the Bay Area.(1) The year-over-year increase in retail revenue was driven primarily by the Company’s enhanced merchandising and pricing initiatives which resulted in, amongst other things, improved product mix, selected pricing changes and higher sell-through of internally produced products. Across Harborside’s retail stores in California, the Company’s branded products represented from 9 to 14 of the 25 top-selling SKUs in Q3 2020.
Total operating expenses for Q3 2020 were approximately $7.8 million, including $1.15 million in one-time costs related to the audit and restatement of prior year financials. This was a 7.5% year-over-year decrease when compared to approximately $8.5 million of costs incurred in Q3 2019. The year-over-year decrease in operating expenses is primarily related to a decrease in general and administrative expenses of $1.1 million to $4.1 million as compared to $5.2 million in Q3 2019, a decrease in allowance for credit losses of $0.3 million, and a decrease in write-downs of receivables, investments and advances of $1.3 million, as no impairments were recorded on any of the Company’s investments in Q3 2020.
During Q3 2020, the Company also recorded an income tax provision of $1.8 million, compared to $1.3 million in Q3 2019, based on estimated federal income taxes payable at period-end.
Operating Income for Q3 2020 was approximately $0.8 million, compared to an operating loss of approximately $3.6 million for Q3 2019. Net loss and comprehensive loss was $2.4 million, compared to a net loss and comprehensive loss of $1.9 million in Q3 2019, a 24.2% decrease on a year-over-year basis. The year over year decrease was due primarily to additional income tax provisions and related interest expense booked during Q3 2020.
Adjusted EBITDA(1) for Q3 2020 was approximately $4.5 million, compared to a negative EBITDA(1) of approximately $0.9 million for Q3 2019, with the year over year increase being driven largely by improved operating efficiencies and headcount reductions across the Company. See “Non-IFRS Financial Measures, Reconciliation, and Discussion.”
Q4 2020 and Full Year Expectations (2)(4)
The Company expects Q4 2020 gross revenues to follow a more historically typical seasonal pattern, with lower flower production and wholesale revenues, resulting in total combined gross revenues of $11 million to $12.5 million for the fourth quarter, with EBITDA(1) for the quarter close to breakeven. For the full year ended December 31, 2020, the Company expects gross revenues in the range of approximately $61 – $63 million, with Adjusted EBITDA(1) for the year in the range of 8 – 10% of revenues.
Liquidity and Cash Balance (2)(3)
As of September 30, 2020, Harborside had approximately $13.3 million in cash. The increase in cash balance since the second quarter of 2020 included a delay in payment of approximately $1.6 million of sales taxes that were due to the state of California. Payment of these taxes was postponed by the state as part of their COVID-19 business relief program and, in accordance with state guidelines, the funds were ultimately remitted at the end of October 2020.
Recent Operational Highlights
Wholesale Operations: Harborside recently announced planned cultivation facility upgrades at the Salinas Facility. The planned upgrades include, among other things, the installation of blackout curtains and supplemental LED grow lights at the Salinas Facility. Following the successful completion of these upgrades, the Company expects an approximately 50% increase in production, an expected approximately 10% increase in bulk wholesale revenue capacity, and an approximately 7% increase in the total productive capacity, on an annualized basis(2)(4). The upgrades are expected to be completed within the first quarter of 2021(2).
In furtherance of its brand strategies, Harborside announced that two of its award-winning in-house brands, Harborside Farms and Key, introduced new product offerings for the market. Key has added ‘Key Mini Pre-Rolls’, a pack of seven 0.5g strain specific pre-rolls, to its product suite. These mini pre-rolls use flower that is sustainably grown in Harborside’s state of the art greenhouses using proprietary techniques. Key also recently offered a new seasonal SKU, ‘Limited Edition Skeleton Key Mini Pre-Rolls’, a nighttime blend of G4 OG and Gelato 33 packed in seven 0.5g mini pre-rolls. Harborside Farms has also added ‘Harborside Farms Quarter Ounces’, which offers strain-specific and single-origin flower from Harborside Farms. The Company also recently commenced sales of clones grown at its Salinas Facility at all Harborside branded retail locations, including Desert Hot Springs.
Capital Markets: During Q3 2020, the Company commenced trading on the OTCQX under the ticker symbol of “HBORF” and, subsequent to the quarter end, Harborside received depository trade clearance (DTC) eligibility.
Acquisitions: Subsequent to Q3 2020, Harborside announced it had executed a definitive agreement with FGW Haight, Inc. (“FGW”) to acquire majority ownership FGW, which holds a dispensary license in the historic Haight-Ashbury District of San Francisco, where the Company expects to start operations in the second quarter of 2021(2).
Secured Indemnity
On November 17, 2020, the Company and its subsidiaries entered into a guaranty and security agreement to guarantee and secure the obligations of the Company to defend and to indemnify its directors and officers (collectively, the “Secured Indemnity“). The Secured Indemnity is intended to supplement coverage available under existing directors and officers insurance maintained by the Company in order to mitigate concerns about claims and potential claims against directors and officers and whether the available insurance applies to and will satisfy in full such claims and potential claims. The scale and complexity of the Company’s operations in a highly regulated sector requires that the directors and officers managing those operations be committed to the performance of their duties without undue or inappropriate distractions. In management’s view, concerns about claims and potential claims and adequacy of insurance may detract from the performance of the directors and officers involved in the Company’s operations or lead to their resignations, which would disrupt the Company’s business. The Board has therefore determined that it is in the best interests of the Company and its subsidiaries to enter into the Secured Indemnity in order to induce the directors and officers to perform their duties to the Company, provide comfort to the directors and officers involved in the Company’s operations and to encourage their ongoing services.
The Secured Indemnity constitutes a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions (“MI 61-101“). The Company is relying on the exemptions from the valuation and the minority approval requirements of MI 61-101 provided for in subsections 5.5(a) and 5.5 (b) and subsection 5.7(a) of MI 61-101, respectively, as the Company’s shares are not listed on specified markets and neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Secured Indemnity, in relation to the interested parties, will represent more than 25% of the Company’s market capitalization, as determined in accordance with MI 61-101.
Harborside Inc., a vertically integrated enterprise with cannabis licenses covering retail, distribution, cultivation, nursery, and manufacturing, is one of the oldest and most respected cannabis companies in the world. Founded in California in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States. Today, the company operates three major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and an integrated cultivation/production facility in Salinas, California. Harborside continues to play an instrumental role in making cannabis safe and accessible to a broad and diverse community of California and Oregon consumers. Harborside is currently a publicly listed company, trading on the CSE under the ticker symbol “HBOR” and the OTCQX under the ticker symbol “HBORF”. Additional information regarding Harborside is available under Harborside’s SEDAR profile atwww.sedar.com.
